Merrimack Pharmaceuticals' MM-121 Demonstrates positive signal in two phase 2 ER/PR+ breast cancer studies


Tuesday, 26 Nov 2013 07:00am EST 

Merrimack Pharmaceuticals Inc:Says the results of two Phase 2 studies evaluating MM-121 in the treatment of women with ER/PR+, HER2 negative breast cancer.Says one study was conducted in metastatic breast cancer (mBC) in combination with exemestane.Says the second was conducted in the neoadjuvant setting in combination with paclitaxel followed by doxorubicin and cyclophosphamide.Says MM-121 is a monoclonal antibody designed to target the ErbB3 (HER3) receptor and to interfere with growth factor-mediated resistance to standard-of-care therapies.Says results from the Phase 2 Study of MM-121 in Combination with Exemestane in Metastatic ER/PR+, HER2 Negative Breast Cancer.Says this study evaluated whether the combination of MM-121 and exemestane was more effective in prolonging progression free survival (PFS) than exemestane in ER/PR+ mBC patients (n=118) who have previously failed anti-estrogen therapy. 

Company Quote

11.19
0.28 +2.57%
26 Dec 2014